Zynerba Pharmaceuticals, Inc. Income Statement | Understand Stock

Login

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of operations

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Foreign exchange (loss) gain
Loss on disposal of equipment
Total other income (expense)

Income tax benefit
Net loss
Net loss per share basic
Net loss per share diluted
Basic weighted average shares outstanding
Diluted weighted average shares outstanding

Loading...

Comments